Abstract Number: 852 • 2012 ACR/ARHP Annual Meeting
C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis
ABSTRACT:Background/Purpose: The currently available clinical markers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In…Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]Abstract Number: 814 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Background/Purpose: Gout has long been recognised to cluster within families. However, formal evidence for familial aggregation is scant and discordant and the magnitude of any…Abstract Number: 815 • 2012 ACR/ARHP Annual Meeting
Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Background/Purpose: In patients with gout, tophi are strongly associated with radiographic damage. Effective urate-lowering therapy (ULT) reduces tophus size. However, no studies to date have…Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…Abstract Number: 819 • 2012 ACR/ARHP Annual Meeting
Trajectories of Change in Physical Function: Effects On Fractures and Mortality
Background/Purpose: Prior studies have identified poor physical function as a risk factor for fractures and mortality. However, these studies did not consider change in physical…Abstract Number: 820 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Incident Fractures Are Associated with an Increased Risk of Cardiovascular Events
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk for both fracture (fx) and cardiovascular disease (CVD) and there is increasing evidence establishing a…Abstract Number: 821 • 2012 ACR/ARHP Annual Meeting
Association of Serum Uric Acid and Incident Fractures in Elderly Men
Background/Purpose: Normal mineral metabolism is critical for skeletal integrity. Uric acid (UA) is produced from purines by the enzyme xanthine oxidase, and elevated levels may…Abstract Number: 822 • 2012 ACR/ARHP Annual Meeting
Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis
Background/Purpose: Women and men with RA are at an increased risk for fracture [fx] as well as greater overall mortality. It is recognized that in…Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…Abstract Number: 824 • 2012 ACR/ARHP Annual Meeting
Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial
Background/Purpose: Denosumab (a RANK ligand antibody) reduces remodeling, increases bone mineral density, and reduces cortical porosity in postmenopausal women with osteoporosis. In FREEDOM, denosumab…Abstract Number: 825 • 2012 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Important Determinants of Cardiovascular Disease in Rheumatoid Arthritis
Background/Purpose: Cardiovascular disease(CVD) represents a major comorbidity and the leading cause of mortality for Rheumatoid arthritis(RA) patients. Unfortunately traditional risk factors for CVD underperform in…Abstract Number: 826 • 2012 ACR/ARHP Annual Meeting
Predictors of Return to Work During 3 Years After Start of First Tumor Necrosis Factor Antagonist in a National Cohort of Biologics-Treated Patients with Rheumatoid Arthritis
Background/Purpose: To estimate predictors of return to work during 3 years following start of anti-TNF therapy in working-age RA patients with total work disability at…